Related Experiment Videos
GABA-ergic drugs: exit stage left, enter stage right
Heather Ashton1, Allan H Young
1Department of Psychiatry, University of Newcastle upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Journal of Psychopharmacology (Oxford, England)
|July 23, 2003
Summary
Newer drugs enhancing gamma-aminobutyric acid (GABA) activity, distinct from older benzodiazepines, show promise for epilepsy, mood disorders, anxiety, and pain. Their long-term effects regarding dependence and withdrawal require further investigation.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Traditional GABA(A) receptor modulators like benzodiazepines were widely used but associated with dependence and withdrawal.
- Focus has shifted to novel GABA-ergic drugs acting via different mechanisms, offering potential alternatives.
Purpose of the Study:
- To review the properties and therapeutic potential of a new generation of GABA-ergic drugs.
- To explore their applications beyond epilepsy, including affective and pain disorders.
Main Methods:
- Literature review of existing studies on novel GABA-ergic drugs.
- Analysis of their pharmacological mechanisms and clinical applications.
Main Results:
- Newer GABA-ergic drugs (e.g., gabapentin, pregabalin) show efficacy in epilepsy.
- These drugs also demonstrate potential in treating bipolar depression, anxiety disorders, and pain conditions.
Conclusions:
- The new generation of GABA-ergic drugs offers broader therapeutic applications than traditional agents.
- Long-term safety profiles, including tolerance and dependence, need continued evaluation.